This poster presents findings that support the benefit of long-acting injectable paliperidone palmitate initiation early in schizophrenia illness. A patient-level meta-analysis was conducted to evaluate the efficacy and safety of long-acting injectable PP versus oral antipsychotics in study participants with schizophrenia by duration of illness (0-3 versus >3 years). Numerically fewer treatment failures and a significantly lower risk of treatment failure were observed with PP versus OAP, regardless of duration of illness. Safety of PP was consistent across groups.